Understanding immune system interplay to improve organ transplant success

May 31, 2018, Babraham Institute
Credit: Babraham Institute

A rare opportunity to analyse both blood and tissue samples from human transplant recipients has allowed immunology researchers at the Babraham Institute to pinpoint how an immunosuppressive drug works to prevent the production of antibodies against the transplanted tissue. This understanding, gained through working together with transplant research immunologists in Oxford, may lead to improved ways of identifying transplant recipients at risk of rejection and treating autoimmune disease.

As described in a paper published today, the researchers assessed the effect of treatment with an immunosuppressive drug called tacrolimus on a type of immune cell called T follicular helper (Tfh). These cells are central to the production of antibodies and are a target of therapeutic strategies to manage unwanted destructive antibodies, for example in auto-immune diseases or in organ transplantation.

Blood and samples were analysed from 61 kidney , some of which had been treated with tacrolimus before the transplant operation. Using both blood and lymph node samples allowed the comparison of circulating with their counterparts residing in the lymph nodes.

The researchers identified that tacrolimus specifically reduced the number of both circulating Tfh cells and Tfh cells found in the lymph nodes. Confirming this is important for monitoring donor recipients post-transplant which can only be done using blood samples. Reduced numbers of Tfh cells overall would be expected to correlate with suppressed organ rejection whereas a high Tfh cell number would be indicative of an immune response potentially causing organ damage.

Babraham Institute group leader and joint senior author, Dr. Michelle Linterman, said: "Now we have identified tacrolimus as a drug that can inhibit T follicular helper cells and reduce the formation of antibodies, it suggests we can use this drug as a way to treat conditions where the action of T follicular helper cells is an underlying cause of disease."

These findings identify the diagnostic relevance of using Tfh cells as a biomarker to assess the immunosuppression status of organ recipients. They point to developments in patient care based upon the status of their immune system, giving a more accurate picture than allowed by current methods monitoring the levels of immunosuppressive drugs in the body.

Explore further: Transplanted livers help body defend against organ rejection, study finds

More information: Elizabeth F. Wallin et al, The Calcineurin Inhibitor Tacrolimus Specifically Suppresses Human T Follicular Helper Cells, Frontiers in Immunology (2018). DOI: 10.3389/fimmu.2018.01184

Related Stories

Transplanted livers help body defend against organ rejection, study finds

April 18, 2018
For decades, transplant experts have observed that liver transplant recipients often need less anti-rejection medication, known as immunosuppressive drugs, than recipients of other solid organs. Similarly, when patients receive ...

Clinical trial does not support the use of bortezomib for kidney transplant recipients

December 14, 2017
A new clinical trial looks at the potential of a new treatment for transplant rejection. The findings, which appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN), do not support the use ...

Study identifies genes involved in tolerance following kidney transplantation

November 30, 2017
A new study provides insights on the mechanisms that allow an individual's immune system to accept, rather than reject, a donor kidney. The findings, which appear in an upcoming issue of the Journal of the American Society ...

Weaning transplant recipients from their immunosuppressive drugs

December 12, 2011
Transplant surgeons live in the hope that one day they will be able to wean at least some of their patients off the immunosuppressive drugs that must be taken to prevent rejection of a transplanted organ. A team of researchers ...

Drug could cut transplant rejection

November 21, 2017
A diabetes drug currently undergoing development could be repurposed to help end transplant rejection, without the side-effects of current immunosuppressive drugs, according to new research by Queen Mary University of London ...

Biomarkers can help guide immune-suppressing treatment after organ transplantation

March 16, 2016
Recently discovered biomarkers may provide valuable new approaches to monitoring immunosuppressive drug therapy in organ transplant recipients—with the potential for individualized therapy to reduce organ rejection and ...

Recommended for you

Researchers uncover immune cell dysfunction linked to photosensitivity

August 16, 2018
Researchers at Hospital for Special Surgery (HSS) have discovered that a type of immune cell known as Langerhans appears to play an important role in photosensitivity, an immune system reaction to sunlight that can trigger ...

Chemicals found in vegetables prevent colon cancer in mice

August 14, 2018
Chemicals produced by vegetables such as kale, cabbage and broccoli could help to maintain a healthy gut and prevent colon cancer, a new study from the Francis Crick Institute shows.

Researchers artificially generate immune cells integral to creating cancer vaccines

August 14, 2018
For the first time, Mount Sinai researchers have identified a way to make large numbers of immune cells that can help prevent cancer reoccurrence, according to a study published in August in Cell Reports.

Doctors may be able to enlist a mysterious enzyme to stop internal bleeding

August 14, 2018
Blood platelets are like the sand bags of the body. Got a cut? Platelets pile in to clog the hole and stop the bleeding.

Team finds missing immune cells that could fight lethal brain tumors

August 13, 2018
Glioblastoma brain tumors can have an unusual effect on the body's immune system, often causing a dramatic drop in the number of circulating T-cells that help drive the body's defenses.

The medicine of the future against infection and inflammation?

August 13, 2018
Researchers at Lund University in Sweden, have in collaboration with colleagues in Copenhagen and Singapore, mapped how the body's own peptides act to reduce infection and inflammation by deactivating the toxic substances ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.